LifeX Labs, a Pittsburgh-based startup incubator, announced Friday that its portfolio company created to address genetic diseases — NeuBase Therapeutics — will merge with New York-based Ohr Pharmaceuticals. Dr. Dietrich A. Stephan, who had served as CEO of LifeX, will lead the newly combined company.
NeuBase was created a little over a year ago to develop a modular peptide-nucleic acid antisense oligonucleotide platform to provide a single, cohesive approach toward genetic diseases caused by…
